Change in Preferred Drug List Status for the Macrolides-Ketolides Drug Class Effective Nov. 7, 2023

In response to the shortage of the preferred brand name product Eryped 200 MG/5 ML suspension, HHSC removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension on the preferred drug list (PDL). The preferred status of the brand name Eryped 200 MG/5 ML suspension (NDC 24338013213) will not change to allow for any existing stock available to be utilized. HHSC removed the non-preferred status for the following drugs, effective Nov. 7.

These changes will allow providers to prescribe the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients.